Key result
Endothelial MYH9 depletion inhibits LDL transcytosis and reduces early atherosclerotic plaque formation.
Answers are grounded in this paper and cite their sources.
Endothelial MYH9 is required for LDL exocytosis and its depletion reduces LDL transcytosis and early atherosclerosis in preclinical models.
Background: In early atherosclerosis, circulating Low-Density Lipoprotein (LDL) crosses the endothelium by transcytosis. This involves caveolar uptake of LDL by scavenger receptor BI (SR-BI) and activin-like kinase 1 (ALK1) and requires the protein caveolin-1 (Cav-1). We identified mediators of LDL transcytosis by isolating membrane microdomains enriched in caveolin-1 from human coronary endothelial cells (HCAECs) treated with LDL and performing mass spectrometry. One of the proteins identified was myosin-9 (MYH9). Methods: Total internal reflection fluorescence microscopy was conducted to measure LDL transcytosis by HCAECs. We measured LDL transcytosis in vivo in mice lacking endothelial MYH9 (EC- Myh9 −/− ). Atherosclerosis studies were also performed in EC- Myh9 −/− deleted of hepatic LDLR via (adeno-associated virus, AAV)-CRISPR. Additionally, we performed analysis of human transcriptomic data. Results: Gene ontology analysis in human aortic endothelial cells suggested a role for MYH9 in exocytosis. Both knockdown and pharmacologic inhibition of MYH9 inhibited LDL transcytosis. MYH9 depletion caused an accumulation of LDL-containing vesicles at the base of the cell; overexpression caused an increase in LDL exocytosis. EC- Myh9 −/− mice accumulated less LDL in the aortic arch after acute injection with LDL. To investigate the role of MYH9 in atherosclerosis, we deleted hepatic LDL in EC- Myh9 −/− mice using AAV-CRISPR and fed them a high-fat diet. The aortic arch and root of AAV-CRISPR; EC- Myh9 −/− mice exhibited smaller plaques. Human transcriptomic data showed greater messenger RNA (mRNA) levels of aortic MYH9 in atherosclerotic aortas compared to healthy controls. Conclusions: Lipid raft proteomics identified MYH9 as a regulator of LDL transcytosis. MYH9 is required for endothelial LDL exocytosis and contributes to early atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2025) studied Atherosclerosis. MYH9 depletion or inhibition vs. Wild-type or healthy controls was evaluated on LDL transcytosis and atherosclerotic plaque size. Endothelial MYH9 depletion inhibited LDL transcytosis and resulted in smaller atherosclerotic plaques in mice, identifying MYH9 as a key regulator of early atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: